MSP Recovery Announces Strategic Term Sheet Providing Prospective Liquidity and Restructuring of Existing Agreements to Remove Corporate Guaranteed Debt by over $1.2 Billion as Well as New Agreements Aimed at Driving Future Growth

MIAMI, April 10, 2025 (GLOBE NEWSWIRE) — MSP Recovery, Inc. (NASDAQ: MSPR) (“MSP Recovery” or the “Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, is pleased to announce that it entered into a strategic term sheet (“Term Sheet”) agreeing to several restructuring transactions with Hazel Partners Holdings, LLC (“Hazel”), Virage Capital Management (“Virage”), and their respective affiliates. These initiatives are designed to reduce costs of the Company through a New Servicer entity (as defined below), deleverage the Company by converting certain debt of significant creditors into equity and release $1.2 billion of debt guaranteed by the Company, provide access to $9.75 million of bridge funding to the Company (of which $6.5 million remains available through July 2025) and up to $25 million working capital for New Servicer, and to focus the Company’s operations, through the New Servicer, on the core business model of pursuing recoveries under the MSP Laws so that it can achieve its long-term recovery goals. The Company has also obtained a payment extension and waiver from YA II PN, Ltd. (“Yorkville”), which allows the Company to continue its original core business as well as develop new and existing tools. In addition to the summary herein, additional information is set forth in greater detail in the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on April 10, 2025. Execution of definitive agreements and closing of the restructuring are expected no later than April 30, 2025.

The transactions outlined below are subject to, among other things, further negotiation and the execution of definitive agreements, regulatory approvals, certain third-party consents and approvals, and shareholder approvals if required by the Nasdaq Stock Market. The obligation of Hazel to enter into definitive documents is subject to the satisfaction of various conditions precedent, at the sole discretion of Hazel, including, but not limited to, satisfactory finalization of due diligence and all required internal approvals, receipt of certain third-party consents required, and finalization of documentation. Consummation of the transactions contemplated by the Term Sheet are also subject to additional fundings by other parties and certain debt concessions by other stakeholders. As a result, there can be no guarantee that the transactions contemplated by the Term Sheet will be consummated.

Transactions Overview

In collaboration with Hazel and Virage, MSP Recovery has agreed to initiate a comprehensive corporate restructuring and funding plan designed to reinforce its financial stability, support operational growth, and streamline recovery servicing. Key components of the contemplated restructuring include:

  • Operational Funding to New Servicer
    Hazel would provide up to $25 million in operational funding through a structured facility to the New Servicer, funded in tranches of up to $1.75 million per month, subject to meeting certain milestones beginning on September 2025, with a maturity date of June 30, 2027. This funding would create a new servicer subsidiary of MSP Recovery (the “New Servicer”) on a go forward basis and will support the buildout of a dedicated team to provide technology-enabled recovery services for Medicare Secondary Payer (MSP) claims and similar matters. The New Servicer’s directors and management team would be independent from the Company and outside of its control. The team would manage a scalable servicing platform built on MSP Recovery’s proprietary data systems.
  • Operational Funding to Company
    Hazel has agreed to provide up to $9.75 million of bridge funding to the Company (of which $6.5 million remains available through July 2025) in additional bridge loan funding to the Company under the existing Operational Collection Floor facility. This brings Hazel’s total funding under the facility to $25.75 million. Beyond July 2025, the MSP Principals have committed to pledge $25 million of collateral to backstop additional working capital requirements of the Company, in addition to the Company’s existing sources of funding such as cash proceeds from the sale of Class A Common Stock to Yorkville pursuant to the Yorkville SEPA and proceeds from claims recoveries, subject to lien repayment on certain claims. In addition, the Company’s annual costs, after currently planned cost reductions, are estimated to be reduced by $5.6 million per annum due to New Servicer operations and funded by the Funder (through New Servicer).
  • Enhanced Servicing Operation
    The Company plans to establish a servicing operation that will be 100% dedicated to recovering claim rights. MSP Recovery would continue to own 100% of all IP rights that it has developed, which it will license to the New Servicer, and a newly appointed and independent CEO will manage the New Servicer. The Company’s objective is to create a servicing operation that is scalable, adequately funded, and capable of serving providers, health plans, and the state and federal government.

    The New Servicer would have an independent board composed of two world-class experienced executives with experience in legal, data, and healthcare, and an existing board member from MSP Recovery. Lender Hazel would approve the independent board members of the New Servicer. This partnership is expected to enhance the Company’s IT/Data know-how and recovery processes.

  • Debt Restructuring

In exchange for a 43% equity interest in the Company (inclusive of shares currently held and those shares acquired through warrant exercises) Virage has agreed to waive all claims and release all liens against the Company relating to the VRM Full Return (approximately $1.2 billion as of March 31, 2025), and the Parties agree that the VRM Full Return will be paid only from: (i) a junior lien against Subrogation Holdings, LLC proceeds, (ii) claims currently owned by Virage, (iii) liens over two tranches of claims currently owned by Hazel (which Hazel shall release as part of the reorganization transaction) and (iv) a non-recourse second lien up to $100 million over 50% of the proceeds from the New Servicer and associated SPVs, to the extent that the VRM Full Return has not been repaid.

In addition, the MSP Principals have agreed to convert 100% of the Company’s debt obligation to them, totaling approximately $144 million, into shares of the Company’s Class A Common Stock, the full and final amount of the debt-to-equity conversion is subject to tax analysis and approval of the MSP Principals and the Company’s Board of Directors.

Hazel’s existing loans to Subrogation Holdings and the amount of Company’s guaranty (currently approximately $100 million) remain unchanged except that such lien shall now exclude the Company’s intellectual property. Hazel agreed, subject to obtaining third-party consents, to extend the maturity date on all outstanding obligations to November 30, 2026. To secure the repayment of the existing Hazel loans to the extent such loans have not been repaid in full, the Company shall, for a principal amount of up to $235 million with an interest rate of SOFR plus 10% per annum: (i) pledge to Hazel 50.1% of the New Servicer and associated SPV equity interests; and (ii) grant a lien over 50% of the proceeds from New Servicer and associated SPVs, once the New Servicer funding has been repaid. In addition, to the extent the VRM Full Return has not been repaid, Virage has second lien of up to $100 million over 50% of the proceeds from New Servicer and associated SPVs.

  • Significant Reduction in Guaranteed Debt of MSP Recovery
    Upon consummation of the proposed transactions, the Company will have reduced $1.2 billion of corporate guarantees of MSP Recovery and reduced its liability to principals John H. Ruiz and Frank C. Quesada by approximately $144 million, assuming full conversion of the debt.
  • Extension of Yorkville Obligation

In addition, Yorkville has agreed to extend the deadline for the Company’s debt obligations to November 30, 2026, in alignment with the Company’s corporate restructuring plan. Under the terms of the Standby Equity Purchase Agreement dated November 14, 2023, as amended, Yorkville waived the Volume Threshold and Maximum Advance Amount limitations, thus increasing the potential for the Company to raise capital by selling shares of its stock to Yorkville over time.

These strategic actions collectively reduce legacy liabilities and provide a sustainable platform for MSP Recovery’s next phase of growth.

“These transactions represent a critical turning point for MSP Recovery,” said John H. Ruiz, Founder and CEO of MSP Recovery. “By aligning with strategic partners and securing operational funding, we believe we have established a foundation that not only addresses past challenges but positions us for long-term growth. The Company appreciates the continued partnership and collaborative approach of its various partners.”

About MSP Recovery

Founded in 2014, MSP Recovery has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries from responsible parties. MSP Recovery innovates technologies and provides comprehensive solutions for multiple industries including healthcare and legal. For more information, visit: msprecovery.com.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” and “will” or, in each case, their negative, or other variations or comparable terminology. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance or results and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by MSP Recovery herein speaks only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for the Company to predict or identify all such events or how they may affect it. MSP Recovery has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, the Company’s ability to capitalize on its assignment agreements and recover monies that were paid by the assignors; the inability of MSP Recovery to obtain financing and generate revenues sufficient to cover the cost of operations; the inherent uncertainty surrounding settlement negotiations and/or litigation, including with respect to both the amount and timing of any such results; the validity of the assignments of claims to MSP Recovery; the ability to successfully expand the scope of the Company’s claims or obtain new data and claims from the Company’s existing assignor base or otherwise; the Company’s ability to innovate and develop new solutions, and whether those solutions will be adopted by the Company’s existing and potential assignors; negative publicity concerning healthcare data analytics and payment accuracy; and those additional factors included in MSP Recovery’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by it with the Securities and Exchange Commission. These statements constitute the Company’s cautionary statements under the Private Securities Litigation Reform Act of 1995.

For Media Inquiries:
[email protected]

For Investor Inquiries:
[email protected]



Accel Entertainment Appoints Gaming Industry Veteran Cheryl Kondra to Board of Directors

Accel Entertainment Appoints Gaming Industry Veteran Cheryl Kondra to Board of Directors

CHICAGO–(BUSINESS WIRE)–
Accel Entertainment, Inc. (NYSE: ACEL) (“Accel” or the “Company”), a leading provider of full-service gaming solutions to local businesses across the U.S., today announced the appointment of Cheryl Kondra to its Board of Directors, effective immediately.

Kondra brings to Accel more than two decades of experience leading audit and compliance activities for public companies in the gaming industry, including Caesars Entertainment, Genting Americas, and Pinnacle Entertainment. Upon joining the board, Kondra will bring her breadth and depth of knowledge to the team as Chair of the board’s Audit Committee.

CEO Andy Rubenstein commented, “With Cheryl’s deep expertise in the casino and gaming sector, we are confident her insights will help us further our goal of becoming best-in-class in audit and compliance in the gaming industry and position us to capture new opportunities which align with our expansion strategy. We welcome Cheryl to the board and look forward to her guidance as we expand into the brick-and-mortar retail and casino space.”

Kondra is currently the VP of Internal Audit for Tractor Supply Company, the largest rural lifestyle retailer in the U.S. Prior to that, she served as VP of Internal Audit and Chief Compliance Officer at Pinnacle Entertainment, where she strengthened and formalized audit and compliance systems with new controls and procedures. She also spent 17 years at Caesars Entertainment, with the last seven years as Chief Audit Executive, where she supported over fifty global locations with regulatory compliance, shared service centralization, business expansion strategy and formalizing controls functions.

Kondra is also currently a member of the Board of Directors of Galaxy Gaming, a developer and distributor of casino systems. She received her Master of Science in Accounting from DeVry University, and her Bachelor of Science in Business Administration from the University of Nevada, Reno.

“I look forward to joining the Accel Board and leaning on my decades of experience working for multi-jurisdictional public gaming companies,” said Kondra. “I am enthusiastic about the opportunity to help guide Accel’s strategic growth and continue building on its strong track record of innovation and compliance in a complex regulatory landscape.”

As part of this transition, Accel also announces that Eden Godsoe has decided not to stand for re-election to the Board, marking the conclusion of her term.

“We are incredibly grateful for Eden’s exceptional leadership and her many contributions during her time on the Board,” commented Karl Peterson, Accel’s Chairman of the Board. “Her insights, efforts, and dedication have been instrumental in guiding the company through key milestones, including our transition to a public company. On behalf of the Board, I want to thank Eden for her years of service and wish her the best in her future endeavors.”

Additionally, Accel is making efforts to implement a more flexible and responsive governance structure, including de-staggering of Board terms. The transition from a three-year to a one-year term structure reflects Accel’s commitment to enhancing shareholder value and ensuring a dynamic leadership framework moving forward.

About Accel

Accel Entertainment, Inc. (NYSE: ACEL) is a leading distributed gaming operator in the United States, as well as a developer of brick-and-mortar racinos and casinos that serve locals gaming markets. Accel is dedicated to delivering unmatched value to its customers through its innovative solutions and exceptional service and is a preferred partner for local business owners in the markets it serves. Accel is the largest terminal operator in the country, supporting more than 26,000 gaming terminals in 4,300 local and regional establishments across ten states. Offering turnkey full-service gaming solutions, Accel designs, manufactures, installs, and operates gaming terminals and related equipment, including slot machines, redemption terminals, video game machines, gaming software, and amusements to authorized non-casino locations including bars, restaurants, convenience stores, truck stops, fraternal and veteran establishments as well as casinos and horseracing venues. For more information, please visit www.accelentertainment.com.

Media Contact

Eric Bonach

H/Advisors Abernathy

212-371-5999

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Casino/Gaming Entertainment

MEDIA:

Logo
Logo

STOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of PLYA, BRKL, RDFN, RDW to Act Now

PR Newswire


NEW YORK
, April 10, 2025 /PRNewswire/ — Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating:

  • Playa Hotels & Resorts N.V. (NASDAQ: PLYA), relating to the proposed merger with Hyatt Hotels Corporation. Under the terms of the agreement, Hyatt will acquire all outstanding shares of Playa for $13.50 per share in cash.

ACT NOW. The Tender Offer expires on April 25, 2025.

Click here for more
https://monteverdelaw.com/case/playa-hotels-resorts-n-v-plya/ It is free and there is no cost or obligation to you.

  • Brookline Bancorp, Inc. (NASDAQ: BRKL), relating to the proposed merger with Berkshire Hills Bancorp, Inc. Under the terms of the agreement, Brookline Bancorp shares will be converted into the right to receive 0.42 of a share of Berkshire Hills Bancorp common stock.

ACT NOW. The Shareholder Vote is scheduled for May 21, 2025.

Click here for more

https://monteverdelaw.com/case/brookline-bancorp-inc-brkl/
. It is free and there is no cost or obligation to you.

  • Redfin Corporation (NASDAQ: RDFN), relating to the proposed merger with Rocket Companies. Under the terms of the agreement, Redfin shares will be converted into the right to receive 0.7926 shares of Rocket’s Class A common stock.

Click here for more
https://monteverdelaw.com/case/redfin-corporation-rdfn/. It is free and there is no cost or obligation to you.

  • Redwire Corporation (NYSE: RDW), relating to the proposed merger with Edge Autonomy Ultimate Holdings, LP. Under the terms of the agreement, Redwire will acquire Edge Autonomy using $150M in cash and $775M in shares of Redwire common stock.

Click here for more

https://monteverdelaw.com/case/redwire-corporation-rdw/
. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk to a lawyer and ask:

  1. Do you file class actions and go to Court?
  2. When was the last time you recovered money for shareholders?
  3. What cases did you recover money in and how much?

About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No company, director or officer is above the law. If you own common stock in any of the above listed companies and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2025 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stockholder-alert-the-ma-class-action-firm-encourages-shareholders-of-plya-brkl-rdfn-rdw-to-act-now-302426144.html

SOURCE Monteverde & Associates PC

Fastly to Announce First Quarter 2025 Financial Results

Fastly to Announce First Quarter 2025 Financial Results

SAN FRANCISCO–(BUSINESS WIRE)–Fastly, Inc. (NYSE: FSLY), a leader in global edge cloud platforms, will release financial results for the first quarter of 2025 after market close on Wednesday, May 7, 2025. Fastly will host an investor conference call that day to discuss its results at 1:30 p.m. PT / 4:30 p.m. ET.

Date:

Wednesday, May 7, 2025

Time:

1:30 p.m. PT / 4:30 p.m. ET

Webcast:

https://investors.fastly.com

Dial-in:

888-330-2022 (US/CA) or 646-960-0690 (Intl.)

Conf. ID#:

7543239

Please dial in at least 10 minutes prior to the 1:30 p.m. PT start time. A live webcast of the call will be available at https://investors.fastly.com where listeners may log on to the event by selecting the webcast link under the “Quarterly Results” section.

A telephone replay of the conference call will be available at approximately 5:00 p.m. PT, May 7 through May 14, 2025 by dialing 800-770-2030 or 609-800-9909 and entering the passcode 7543239.

About Fastly, Inc.

Fastly’s powerful and programmable edge cloud platform helps the world’s top brands deliver online experiences that are fast, safe, and engaging through edge compute, delivery, security, and observability offerings that improve site performance, enhance security, and empower innovation at global scale. Compared to other providers, Fastly’s powerful, high-performance, and modern platform architecture empowers developers to deliver secure websites and apps with rapid time-to-market and demonstrated, industry-leading cost savings. Organizations around the world trust Fastly to help them upgrade the internet experience, including Reddit, Neiman Marcus, Universal Music Group, and SeatGeek. Learn more about Fastly at https://www.fastly.com, and follow us @fastly.

Source: Fastly, Inc.

Investor Contact

Vernon Essi, Jr.

[email protected]

Media Contact

Spring Harris

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Security Apps/Applications Technology Software Networks Internet

MEDIA:

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 39,740 shares of common stock and 19,830 restricted stock units (“RSUs”) to seven new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $39.12 per share, Mirum’s closing trading price on April 10, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates. The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.

Mirum’s late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.

Investor Contact:

Andrew McKibben

[email protected]

Media Contact:

Erin Murphy

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Orion Properties Inc. Provides 2025 Year-to-Date Highlights and Sets First Quarter 2025 Earnings Release and Webcast Dates

Orion Properties Inc. Provides 2025 Year-to-Date Highlights and Sets First Quarter 2025 Earnings Release and Webcast Dates

– Completed 425,000 Square Feet of Leasing –

– Sold Three Vacant Properties for $19.1 Million –

– Maintains Strong Liquidity –

– Sets Date and Time for First Quarter Release and Webcast –

PHOENIX–(BUSINESS WIRE)–
Orion Properties Inc. (NYSE: ONL) (“Orion” or the “Company”), a fully-integrated real estate investment trust (“REIT”) which owns a diversified portfolio of single-tenant net lease office properties including designated use assets located across the United States, announced today highlights for 2025 through April 10, 2025. The Company also announced that it will release its results for the first quarter of 2025 after market close on Wednesday, May 7, 2025.

  • Leasing: The Company has leased approximately 425,000 square feet in a combination of new and renewal leases, with a weighted average lease term of approximately 7.7 years. Included in this total is a new 15.7-year lease for 46,000 square feet at the Company’s Parsippany, New Jersey property, bringing the formerly vacant property to more than 60% leased to two tenants. Additionally, the Company entered into a new 10.0-year lease for 160,000 square feet at its currently vacant property in Buffalo, New York with Ingram Micro Inc., who will be relocating from Orion’s Amherst, New York property.
  • Property Sales: The Company has closed on the sale of three vacant properties totaling 287,000 square feet for a gross sales price of $19.1 million, or $66 per square foot. Two additional properties, representing 211,000 square feet, are under contract for $27.3 million, or $129 per square foot, and are scheduled to close later in 2025. The Company continues to actively evaluate and market select properties for sale and expects to secure additional dispositions throughout the remainder of the year.
  • Liquidity: The Company’s liquidity remains strong at approximately $243.9 million represented by cash on hand and the available balance on the revolver as of April 10, 2025.

“We have successfully started 2025 with robust leasing momentum that builds upon the 1.1 million square feet of leasing activity we executed on in the prior year, in addition to $46.4 million in vacant or near vacant property asset sales that have closed or will close during the year,” stated Paul McDowell, Orion’s Chief Executive Officer. “Furthermore, we continue to see strong interest in both additional leasing and disposition pipeline opportunities while continuing to maintain strong liquidity in these uncertain times. We remain focused on executing our strategic initiative to shift our portfolio composition toward more dedicated use assets such as flex, laboratory, medical and governmental properties.”

Webcast and Conference Call Information

Orion will host a webcast and conference call to review its results at 10:00 a.m. ET on Thursday, May 8, 2025. The webcast and call will be hosted by Paul McDowell, Chief Executive Officer and President, and Gavin Brandon, Chief Financial Officer, Executive Vice President and Treasurer. To participate, the webcast can be accessed live by visiting the “Investors” section of Orion’s website at onlreit.com/investors. To join the conference call, callers from the United States and Canada should dial 1-844-539-3703, and international callers should dial 1-412-652-1273, ten minutes prior to the scheduled call time.

Replay Information

A replay of the webcast may be accessed by visiting the “Investors” section of Orion’s website at onlreit.com/investors. The conference call replay will be available after 1:00 p.m. ET on Thursday, May 8, 2025 through 11:59 p.m. ET on Thursday, May 22, 2025. To access the replay, callers may dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use passcode, 13751072.

About Orion Properties Inc.

Orion Properties Inc. is an internally-managed real estate investment trust engaged in the ownership, acquisition and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased primarily on a single-tenant net lease basis to creditworthy tenants. The Company’s portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory and R&D and flex/industrial properties. The Company was founded on July 1, 2021, spun-off from Realty Income (NYSE: O) on November 12, 2021 and began trading on the New York Stock Exchange on November 15, 2021. On March 5, 2025, the Company changed its name from Orion Office REIT Inc. to Orion Properties Inc. to better describe its broader investment strategy to shift its portfolio concentration over time away from traditional office properties, towards more dedicated use assets that have an office component. The Company is headquartered in Phoenix, Arizona and has an office in New York, New York. For additional information on the Company and its properties, please visit onlreit.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including with respect to future performance. These forward-looking statements are based on management’s current expectations and beliefs, but they involve a number of risks and uncertainties that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including, but not limited to: conditions associated with United States commercial real estate markets, including an oversupply of office space, tenant credit and general economic conditions and geopolitical conditions; our ability to renew leases with existing tenants or re-let vacant space to new tenants on favorable terms and in a timely manner, or at all; our ability to sell non-core assets on favorable terms and in a timely manner, or at all; our ability to close pending real estate transactions, which may be subject to conditions that are outside of our control; and our ability to successfully execute on our strategy to shift our portfolio concentration over time away from traditional office properties, towards more dedicated use assets; as well as any other risks reflected in Orion’s filings with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as reflections of Orion’s plans, projections and estimates as of the date of this press release. Actual results may differ materially from what is expressed or forecast in this press release. Orion undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date these statements were made.

Investor Relations Contact:

Email: [email protected]

Phone: 602-675-0338

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo

Homes.com Report: Home Price Increases Slowed for the Third Consecutive Month in March

Homes.com Report: Home Price Increases Slowed for the Third Consecutive Month in March

The median home price increased 2.2% in March over last year. The Northeast and Midwest markets continued to see the strongest price growth

ARLINGTON, Va.–(BUSINESS WIRE)–
Homes.com, a CoStar Group leading online residential marketplace, today released a new report analyzing home prices in March (based on the data collected to date), price trends across major cities, and what the latest developments in the housing market mean for homebuyers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250410980324/en/

Homes.com National Median Home Price March 2025

Homes.com National Median Home Price March 2025

According to the preliminary estimates, home prices continued to go up in March, but the rate of price increases slowed for the third consecutive month. Year-over-year, prices rose 2.2% in March, 2.7% in February, and 3.6% in January. In dollar terms, the median home price went up $8,000 from March of last year to March of this year, rising from $372,000 to $380,000. Prices have increased for 21 consecutive months, with price appreciation peaking at 5.6% in December.

In addition to the slowing price growth in recent months, there was an increase in the number of homes for sale and a small decline in mortgage rates in March. Lower mortgage rates make buying a home more affordable, and more homes for sale equates to higher leverage for homebuyers. Combined, these factors point to a slight shift away from a seller’s market and towards a buyer’s market.

The Northeast and Midwest continued to see the strongest price appreciation in March. Of the 10 markets with the largest price increases, four were in the Northeast, and four were in the Midwest. Cleveland led the way, with prices rising more than 10% in the past year, followed by Chicago, New York, and Pittsburgh. By contrast, the South only had one market, Austin, among the 10 cities with the largest price increases, while five Southern markets were among the bottom 10. Four markets saw price declines in March, with the state of Florida accounting for three of the four. The four markets with declines were Orlando, Jacksonville, San Francisco, and Tampa.

The data shared in this report could change slightly once all home sales are accounted for. Melina Duggal, Senior Director of Market Analytics at CoStar Group and Homes.com, is available for interviews to provide insights on these data and the residential real estate market in general. For more information and insights on the latest home buying and selling market trends, visit Homes.com.

About Homes.com

Homes.com is the fastest-growing residential real estate marketplace and the second largest portal in the United States. Homes.com is a brand of CoStar Group (NASDAQ: CSGP), a global leader in commercial real estate information, analytics, and online marketplaces, which acquired the platform in 2021.

Homes.com is the first major U.S. real estate portal to focus first on helping homeowners and their agents leverage the marketing power of the internet to bring more potential buyers to their listings. Homes.com’s unparalleled content and search capabilities bring millions of buyers and sellers to the site where they can seamlessly connect with agents. On average, Homes.com’s Members are winning 58% more listings* because they offer the home sellers a real estate portal that works for them not against them.

The Homes.com Network reached an audience of 110 million average monthly unique visitors in the fourth quarter ending December 31, 2024.** Consumer brand awareness skyrocketed from 4% to 33% in just one year since CoStar Group launched the industry’s largest marketing campaign to date in February 2024, reintroducing the platform to the market. For more information, visit Homes.com.

* Based on internal analyses comparing Members to non-Members on Homes.com.

** Homes.com Network (which includes Homes.com, the Apartments Network, and the Land Network) average monthly unique visitors for the quarter ended December 31, 2024, according to Google Analytics.

About CoStar Group

CoStar Group (NASDAQ: CSGP) is a global leader in commercial real estate information, analytics, online marketplaces and 3D digital twin technology. Founded in 1986, CoStar Group is dedicated to digitizing the world’s real estate, empowering all people to discover properties, insights, and connections that improve their businesses and lives.

CoStar Group’s major brands include CoStar, a leading global provider of commercial real estate data, analytics, and news; LoopNet, the most trafficked commercial real estate marketplace; Apartments.com, the leading platform for apartment rentals; and Homes.com, the fastest-growing residential real estate marketplace. CoStar Group’s industry-leading brands also include Matterport, a leading spatial data company whose platform turns buildings into data to make every space more valuable and accessible, STR, a global leader in hospitality data and benchmarking, Ten-X, an online platform for commercial real estate auctions and negotiated bids and OnTheMarket, a leading residential property portal in the United Kingdom.

CoStar Group’s websites attracted over 134 million average monthly unique visitors in the fourth quarter of 2024, serving clients around the world. Headquartered in Arlington, Virginia, CoStar Group is committed to transforming the real estate industry through innovative technology and comprehensive market intelligence. From time to time, we plan to utilize our corporate website as a channel of distribution for material company information. For more information, visit CoStarGroup.com.

Matthew Blocher

CoStar Group

(202) 346-6775

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Finance Data Analytics Professional Services Residential Building & Real Estate Construction & Property

MEDIA:

Photo
Photo
Homes.com National Median Home Price March 2025
Photo
Photo
Homes.com National Year-Over-Year Change in Median Home Price March 2025
Photo
Photo
Homes.com National Year-Over-Year Change in Median Home Price 2 March 2025
Photo
Photo
Homes.com National Median Home Prices In The Month of March
Photo
Photo
Homes.com Year-Over-Year Increases in March Home Sale Prices Nationally
Photo
Photo
Homes.com Select Sales Example 2 March 2025
Photo
Photo
Homes.com Select Sales Example 3 March 2025
Photo
Photo
Homes.com Select Sales Example 1 March 2025
Logo
Logo

Titan Acquisition Corp Announces Closing of $276,000,000 Initial Public Offering

BROOKLYN, N.Y., April 10, 2025 (GLOBE NEWSWIRE) — Titan Acquisition Corp (Nasdaq: TACHU) (the “Company”) today announced that it closed its initial public offering of 27,600,000 units at $10.00 per unit, including the issuance of 3,600,000 units as result of the underwriters’ exercise of its over-allotment option in full. The gross proceeds from the offering were $276 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “TACHU” on April 9, 2025.

Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “TACH” and “TACHW”, respectively.

The Company is a blank check company incorporated as an exempted company under the laws of the Cayman Islands, which will seek to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. 

Cantor Fitzgerald & Co. acted as the sole book-running manager in the offering. Odeon Capital Group LLC acted as co-manager of the offering.

The offering was made only by means of a prospectus, copies of which may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 5th Floor, New York, New York, 10022; Email: [email protected], or from the SEC website at www.sec.gov.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (“SEC”) on April 8, 2025.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, www.sec.gov.

Contact:

Titan Acquisition Corp
Mr. Adeel Rouf
Chief Financial Officer, President and Director
131 Concord Street
Brooklyn, NY 11201
Email: [email protected]



Halozyme Announces FDA Approval of argenx’s VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

PR Newswire


SAN DIEGO
, April 10, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

VYVGART® Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able to self-inject after proper instruction in subcutaneous injection technique.

The single dose prefilled subcutaneous injection was developed as part of argenx’s exclusive partnership with Halozyme on their ENHANZE® drug delivery technology, which enables rapid, high-volume delivery of biologics

“The FDA approval of VYVGART Hytrulo prefilled syringe represents a significant advancement in treatment options for gMG and CIDP patients, enabling self-administration by patients and potentially further reducing the burden of treatment,” said Dr. Helen Torley, president and chief executive officer of Halozyme. “We are delighted that argenx continues to expand use of Halozyme’s proven ENHANZE technology to support patient independence and convenience.”

The approval of VYVGART® Hytrulo prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to VYVGART® Hytrulo in a vial. In addition, human factors validation studies demonstrated that participants with gMG or CIDP, or their caregivers, safely and successfully prepared and administered VYVGART® Hytrulo with the prefilled syringe. Previous FDA approval of VYVGART® Hytrulo for patients with gMG and CIDP was based on the global Phase 3 ADAPT, ADAPT-SC and ADHERE trials.

About Halozyme

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN.Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations by enabling self-administration and broadening the treatment options for the indication referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “expect,” “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner’s product referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme’s most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
[email protected]

Samantha Gaspar

Teneo
212-886-9356
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-announces-fda-approval-of-argenxs-vyvgart-hytrulo-prefilled-syringe-co-formulated-with-enhanze-for-self-injection-for-generalized-myasthenia-gravis-and-chronic-inflammatory-demyelinating-polyneuropathy-302426123.html

SOURCE Halozyme Therapeutics, Inc.

Oncolytics Biotech® Funds Pelareorep’s Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

PR Newswire


SAN DIEGO and CALGARY, AB
, April 10, 2025 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement (SPA) with Alumni Capital LP (Alumni), an institutional investor. This partnership will provide Oncolytics with a flexible source of funding, enabling the Company to progress pelareorep toward key clinical milestones and minimize dilution to create and sustain shareholder value. The SPA allows Oncolytics to be judicious and plan for the timing and amount of any equity sales, which will be critical as pelareorep’s development continues.

Under the terms of the agreement, Oncolytics has the right to sell, and Alumni has the obligation to purchase up to US$20 million worth of common stock over a 15-month period at prices that are based on the market price at the time of each sale to Alumni. Oncolytics, at its sole discretion, controls the timing and amount of all sales of common stock, and there are no warrants, derivatives, or other share classes associated with the SPA. In relation to the execution of the SPA, Oncolytics issued to Alumni 816,326 commitment shares and may issue to Alumni an additional 816,326 commitment shares pro rata upon the delivery of purchase notices under the SPA.

The common shares that may be issued by the Company through the SPA have been conditionally approved for listing on the Toronto Stock Exchange (“TSX”), and the required notices related to the SPA have been filed with the Nasdaq. In obtaining TSX listing approval, the Company has relied on the “Eligible Interlisted Issuer” exemption from TSX rules under section 602.1 of the TSX Company Manual.

No offers or sales of common shares will be made in Canada or through the facilities of the TSX or any other marketplace in Canada.

The common shares under the SPA will be offered and sold to Alumni and may be reoffered and resold by Alumni to the public pursuant to a short form base shelf prospectus (the “Base Shelf Prospectus”) as accompanied by a prospectus supplement (the “Prospectus Supplement”) and pursuant to a prospectus supplement to a base shelf prospectus forming part of the Company’s registration statement on Form F-10 (together with any amendments thereto, the “Registration Statement”) registering the common shares under the United States Securities Act of 1933, as amended, pursuant to the Multi-Jurisdictional Disclosure System adopted by the United States and Canada. The final prospectus supplement has been filed with the securities commissions and other similar regulatory authorities in the province of Alberta and the United States. There will not be any sale of common shares in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such province, state or jurisdiction.

Access to the Prospectus Supplement, the Base Shelf Prospectus and any amendments thereto are provided in Canada and the United States in accordance with securities legislation relating to the procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment to such documents. The Base Shelf Prospectus and the Prospectus Supplement are accessible through SEDAR+ and the Registration Statement, the base shelf prospectus contained therein and the prospectus supplement thereto is accessible through EDGAR at www.sec.gov. An electronic or paper copy of these documents may be obtained, without charge, by contacting the Company at Suite 804, 322 – 11th Avenue SW, Calgary, Alberta T2R 0C5, telephone: (403) 670-7377, email: [email protected]. with an email address or mailing address, as applicable. No securities regulatory authority has either approved or disapproved of the contents of this news release.

A copy of the SPA is available in the Company’s Form 6-K that has been filed with the Securities and Exchange Commission.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these common shares in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding Oncolytics’ belief about the possible sales of common shares, statements regarding how Oncolytics intends to use the proceeds from the sale of common shares, our belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our plans for combination clinical trials with pelareorep in solid malignancies as we advance towards registrational studies in metastatic breast cancer and pancreatic cancer and other statements related to anticipated developments in Oncolytics’ business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics’ actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics’ ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics’ quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

Company Contact 

Jon Patton

Director of IR & Communication
[email protected] 

Investor Relations for Oncolytics

Mike Moyer

LifeSci Advisors
+1-617-308-4306
[email protected] 

Media Contact for Oncolytics

Michael Rubenstein

LifeSci Communications
[email protected]

Logo – https://mma.prnewswire.com/media/2408622/5262825/Oncolytics_Biotech_Inc_Logo.jpg

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-funds-pelareoreps-ongoing-clinical-development-with-a-share-purchase-agreement-in-partnership-with-alumni-capital-302426126.html

SOURCE Oncolytics Biotech® Inc.